Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05425745 | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. | PHASE3 | COMPLETED | 354 | — | — | Jul 1, 2022 | May 1, 2024 | Jun 10, 2025 | - | — |
| NCT05142722 | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | PHASE3 | COMPLETED | 2,530 | — | — | Dec 1, 2021 | Sep 1, 2024 | Sep 18, 2025 | - | — |
| NCT05266586 | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | PHASE2 | COMPLETED | 119 | — | — | Mar 1, 2022 | Sep 1, 2022 | Jul 2, 2024 | - | — |
| NCT04753606 | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy | PHASE2 | COMPLETED | 120 | — | — | Feb 1, 2021 | Aug 1, 2021 | Jul 11, 2024 | - | — |
| NCT04770389 | Randomized Study of Obicetrapib in Combination With Ezetimibe | PHASE2 | COMPLETED | 112 | — | — | Feb 1, 2021 | Jun 1, 2021 | Apr 23, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| Obicetrapib | DRUG | 10 mg Obicetrapib tablet |
| Placebo | DRUG | placebo tablet made to resemble active |
| Ezetimibe 10mg | DRUG | capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule. |
| Obicetrapib placebo | OTHER | tablets; no active ingredient |
| Ezetimibe placebo | OTHER | capsules; no active ingredient |
| Obicetrapib 5mg | DRUG | tablet |